BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C ...
Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways - - Data from ...
Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial ...
Werewolf Therapeutics, Inc. (the "Company” or "Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...
First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with ...
NDAQ:BCYC) Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback